€26.51
0.32% yesterday
Xetra, Nov 06, 05:39 pm CET
ISIN
DE000BAY0017
Symbol
BAYN

Bayer Stock price

€26.51
-1.84 6.49% 1M
+2.46 10.23% 6M
+7.20 37.26% YTD
+2.57 10.71% 1Y
-27.77 51.16% 3Y
-16.24 37.98% 5Y
-96.94 78.53% 10Y
-5.36 16.82% 20Y
Xetra, Closing price Thu, Nov 06 2025
+0.09 0.32%
ISIN
DE000BAY0017
Symbol
BAYN
Industry

New AI Insights on Bayer Insights AI Insights on Bayer

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
€26.3b
Enterprise Value
€59.2b
Net debt
€32.9b
Cash
€5.5b
Shares outstanding
982.4m
Valuation (TTM | estimate)
P/E
negative | 5.6
P/S
0.6 | 0.6
EV/Sales
1.3 | 1.3
EV/FCF
12.9
P/B
0.9
Dividends
DPS
€0.11
Yield 1Y | 5Y
0.4% | 2.7%
Growth 1Y | 5Y
0.0% | -47.7%
Payout 1Y | 3Y
-4.2% | -191.2%
Increased
0 Years
Financials (TTM | estimate)
Revenue
€46.2b | €46.7b
EBITDA
€6.6b | €9.5b
EBIT
€-1.4b | €6.1b
Net Income
€-3.4b | €4.7b
Free Cash Flow
€4.6b
Growth (TTM | estimate)
Revenue
-2.0% | 0.2%
EBITDA
-32.8% | -25.8%
EBIT
-161.1% | 53.0%
Net Income
-170.0% | 282.8%
Free Cash Flow
-19.3%
Margin (TTM | estimate)
Gross
55.0%
EBITDA
14.3% | 20.3%
EBIT
-2.9%
Net
-7.4% | 10.0%
Free Cash Flow
9.9%
Financial Health
Equity Ratio
28.8%
Return on Equity
-8.0%
ROCE
-1.8%
ROIC
-1.8%
Debt/Equity
1.3
More
EPS
€-3.5
FCF per Share
€4.7
Short interest
-
Employees
91k
Rev per Employee
€510.0k
Show more

Create a Free Account to create an Bayer alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Bayer Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Bayer forecast:

12x Buy
43%
15x Hold
54%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Bayer forecast:

Buy
43%
Hold
54%
Sell
4%

Financial data from Bayer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
46,174 46,174
2% 2%
100%
- Direct Costs 20,802 20,802
5% 5%
45%
25,372 25,372
7% 7%
55%
- Selling and Administrative Expenses 15,312 15,312
2% 2%
33%
- Research and Development Expense 6,150 6,150
12% 12%
13%
6,623 6,623
33% 33%
14%
- Depreciation and Amortization 7,974 7,974
4% 4%
17%
EBIT (Operating Income) EBIT -1,351 -1,351
161% 161%
-3%
Net Profit -3,418 -3,418
170% 170%
-7%

In millions EUR.

Don't miss a Thing! We will send you all news about Bayer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bayer Stock News

Neutral
Business Wire
about 10 hours ago
LEVERKUSEN, Germany--(BUSINESS WIRE)--The Supervisory Board of Bayer AG has appointed Dr. Judith Hartmann to the company's Board of Management, effective March 1, 2026. She will succeed Wolfgang Nickl as the company's Chief Financial Officer (CFO) on June 1, 2026, following his planned retirement at the end of May 2026. Dr. Hartmann is currently an Operating Partner at Sandbrook Capital, a priv...
Neutral
Business Wire
4 days ago
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented in scientific sessions at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas, November 6–9. “Up to 30% of Americans living with type 1 diabetes (T1D) are affected by chronic kidney disease (CKD),1,2 which puts the...
AD HOC NEWS
7 days ago
Bayer DE000BAY0017 hat in den US-Rechtsstreitigkeiten rund um die schon seit Jahrzehnten verbotene Umweltchemikalie PCB einen Rückschlag hinnehmen müssen.
More Bayer News

Company Profile

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Head office Germany
CEO William Anderson
Employees 90,587
Founded 1863
Website www.bayer.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today